What Is the Treatment of Tracheal Cancer When Radical Therapy Is Not an Option?
For patients with tracheal cancer who are not eligible for radical treatment, a structured
palliative approach targets the most burdensome symptoms and aims to maintain airway function
for as long as possible.
Clinical scenario
This protocol applies to tracheal cancer patients for whom radical treatment is not
feasible. The dominant clinical concerns are tumor-related airway narrowing, hemoptysis,
pain, shortness of breath, and cough — each of which drives the selection of palliative
intervention.
Treatment approach — partial overview
Palliative locoregional strategies fall into two main categories: radiotherapy directed
at localized tumor growth to relieve symptoms, and procedural or surgical techniques
to restore and maintain airway patency. Which approach — or combination — is appropriate
depends on tumor extent, dominant symptoms, and expected prognosis. The complete protocol
covers the full selection algorithm, technique options, and advanced modality considerations.
Treatment goals
Response is assessed at 3 months. Success is defined as measurable improvement in
shortness of breath and hemoptysis, restoration of airway patency, and relief of
obstructive symptoms.
References
DOI: 10.3389/or.2024.1451247
- Consider palliative radiotherapy for patients with localized tumor growth who are not candidates for radical treatment [III, B].
- Common indications for palliative radiotherapy include hemoptysis, pain, shortness of breath, and cough [III, B].
- Treatment plans vary, but the median dose typically is around 30 Gy, delivered in a range of fractions.
- Consider palliative surgical treatment for patients with pronounced symptoms of airway obstruction when radical treatment is not feasible [III, B].
- Utilize various endoscopic techniques, such as dilation, laser vaporization, electrocoagulation, cryotherapy, photodynamic therapy, or argon coagulation, to restore the airway lumen [III, B].
- Reserve self-expanding metal stents for patients with an expected survival of 3–6 months, particularly those diagnosed with ACC [IV, B].
- The use of advanced radiotherapy techniques, such as SBRT, proton therapy, neutron therapy, and CIRT, may be considered in the treatment of tracheal carcinoma in highly selective cases, particularly when traditional treatment options are inadequate or infeasible.
- The percentage of patients showing improvement after 3 months of RT was 56.3% for shortness of breath and 72.2% for hemoptysis, with a mean duration of response reaching 12.5 months.
View source ↗